3-硝基苯肼 | 619-27-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-硝基苯肼
• 英文名称: 3-nitrophenylhydrazine
• 英文别名: m-nitrophenylhydrazine；(3-nitrophenyl)hydrazine
• CAS: 619-27-2
• 化学式: C₆H₇N₃O₂
• mdl: MFCD00044581
• 分子量: 153.14
• InChiKey: JFILLLZWNHOVHV-UHFFFAOYSA-N

物化性质

• 熔点：
  92-95 °C
• 沸点：
  317.5±25.0 °C(Predicted)
• 密度：
  1.419±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈（少许）、DMSO（少许）
• 稳定性/保质期：
  1. 稳定性：稳定。 2. 禁配物：强氧化剂、强酸、强还原剂。 3. 避免接触的条件：摩擦、震动或撞击。 4. 聚合危害：不聚合。 5. 分解产物：氮氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.9
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2928000090
• 储存条件：
  储存注意事项： - 储存于阴凉、通风良好的库房。 - 远离火种及热源。 - 包装需密封。 - 应与氧化剂、还原剂、酸类以及食用化学品分开存放，切忌混储。 - 配备相应品种和数量的消防器材。 - 储区应准备合适的材料以收容泄漏物。

制备方法与用途

用途

用于有机合成。[10]

反应信息

• 作为反应物：
  描述：

  3-硝基苯肼 在 palladium on activated charcoal 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 3-吡唑-1-苯胺
  参考文献：
  名称：

  Solvent-free preparation of tris-pyrazolyl-1,3,5-triazines

  摘要：

  Tris-pyrazolyl-1,3,5-triazines have been prepared by cyclotrimerization of aromatic nitriles in solvent-free conditions. The interesting structures of these compounds make them candidates for application in coordination chemistry and crystal engineering. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)00340-4
• 作为产物：
  描述：

  4-硝基氯化重氮苯 在 盐酸 、 sodium dithionite 作用下， 生成 3-硝基苯肼
  参考文献：
  名称：

  Thompson, Journal of the Society of Dyers and Colourists, vol. 37, p. 9

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Visible-Light-Mediated Synthesis of Unsymmetrical Diaryl Sulfides via Oxidative Coupling of Arylhydrazine with Thiol
  作者：Golam Kibriya、Susmita Mondal、Alakananda Hajra

  DOI：10.1021/acs.orglett.8b03549

  日期：2018.12.7

  A metal-free visible-light-promoted oxidative coupling between thiols and arylhydrazines has been developed to afford diaryl sulfides using a catalytic amount of rose bengal as photocatalyst under aerobic conditions. A library of unsymmetrical diaryl sulfides with broad functionalities was synthesized in good yields at room temperature. The present methodology is also applicable to benzo[ d]thiazole-2-thiols

  已经开发出在硫醇和芳基肼之间的无金属的可见光促进的氧化偶合，以在有氧条件下使用催化量的孟加拉红作为光催化剂来提供二芳基硫醚。在室温下以高收率合成了具有广泛功能的不对称二芳基硫醚库。本方法学也适用于苯并[d]噻唑-2-硫醇，苯并[d]恶唑-2-硫醇，1 H-苯并[d]咪唑-2-硫醇和1 H-咪唑-2-硫醇。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Methods of inhibiting BTK and SYK protein kinases
  申请人：Goldstein Michael David

  公开号：US20070219195A1

  公开（公告）日：2007-09-20

  Methods of inhibiting a tyrosine kinase wherein said tyrosine kinase is BTK or SYK comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to formula I are disclosed. The compounds are useful for treating auto-immune and inflammatory diseases.

  抑制酪氨酸激酶的方法，其中所述酪氨酸激酶是BTK或SYK，包括向需要的患者施用根据式I的化合物的治疗有效量。这些化合物可用于治疗自身免疫和炎症性疾病。
• Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts
  申请人：SHANGHAI HYBRID-CHEM TECHNOLOGIES

  公开号：US20190152896A1

  公开（公告）日：2019-05-23

  The present invention provided a continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts. Diazotization, reduction, acidic hydrolysis and salifying with acids are innovatively integrated together. Using acidic liquids of aniline or substituted aniline, diazotization reagents, reductants and acids as raw materials, phenylhydrazine derivative salts is obtained through the synthesis process, which is a three-step continuous tandem reaction including diazotization, reduction, acidic hydrolysis and salifying. The described synthesis process is a kind of integrated solutions, which is carried out in an integrated reactor. The feed inlets of the integrated reactor are continuously filled with raw materials. In the integrated reactor, diazotization, reduction, acidic hydrolysis and salifying are carried out continuously and orderly, and phenylhydrazine salts or substituted phenylhydrazine salts is obtained in the outlet of the integrated reactor without interruption. The total reaction time is no more than 20 min.

  本发明提供了一种连续流程，用于合成苯肼盐和取代苯肼盐。重氮化、还原、酸性水解和酸化与酸类创新地集成在一起。使用苯胺或取代苯胺的酸性液体、重氮化试剂、还原剂和酸类作为原料，通过合成过程获得苯肼衍生物盐，这是一个包括重氮化、还原、酸性水解和酸化的三步连续串联反应。所述的合成过程是一种集成解决方案，是在一个集成反应器中进行的。集成反应器的进料口连续填充原料。在集成反应器中，重氮化、还原、酸性水解和酸化被连续有序地进行，苯肼盐或取代苯肼盐在集成反应器的出口处获得，没有中断。总反应时间不超过20分钟。